Zelira Therapeutics (ASX:ZLD) launches oral care subsidiary in US

[videojs_hls url=’//du7x25at22z7c.cloudfront.net/286759/index_HLSv3.m3u8′ poster=’http://www.finnewsnetwork.com.au/newssystem/Headlines01_360_200908.jpg’]

Global therapeutic medicinal cannabis company, Zelira Therapeutics (ASX:ZLD) has expanded into the dental health market by launching a scientifically formulated, hemp-derived cannabinoid-based oral care products subsidiary.

The company has joined forces with USDA Bio-preferred natural toothpaste developer SprinJene and Health and Natural Beauty USA Corp in this USA-based venture. The company aims to release to the US market a cannabinoid-containing toothpaste, its first over-the-counter product in the USA by Q4 2020.

In addition, Zelira Therapeutics (ASX:ZLD) remains confident that it is on track to deliver four more new products in global markets this year.

Shares in Zelira Therapeutics (ASX:ZLD) are trading 3.45 per cent higher at 6 cents

Copyright 2020 – Finance News Network

Source: Finance News Network